Leap Therapeutics Files 8-K on Financials

TL;DR

LEAP filed an 8-K on Aug 12, 2024, updating financials. Check it out.

AI Summary

On August 12, 2024, Leap Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The company, incorporated in Delaware with its principal executive offices in Cambridge, MA, is involved in the pharmaceutical preparations industry.

Why It Matters

This filing provides investors with an update on Leap Therapeutics' financial condition and operational performance, which is crucial for evaluating the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This is a routine 8-K filing providing standard financial and operational information, not indicating any immediate or significant new risks.

Key Players & Entities

• Leap Therapeutics, Inc. (company) — Registrant
• August 12, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Cambridge, MA (location) — Address of principal executive offices
• 47 Thorndike Street, Suite B1-1 (address) — Principal executive offices
• 001-37990 (filing_number) — SEC File Number
• 27-4412575 (tax_id) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.001 — registered Common Stock, par value $0.001 LPTX Nasdaq Capital Market Indicate

Filing Documents

• tm2421304d1_8k.htm (8-K) — 27KB
• tm2421304d1_ex99-1.htm (EX-99.1) — 104KB
• tm2421304d1_ex99-1img01.jpg (GRAPHIC) — 10KB
• 0001104659-24-088051.txt ( ) — 321KB
• lptx-20240812.xsd (EX-101.SCH) — 3KB
• lptx-20240812_lab.xml (EX-101.LAB) — 33KB
• lptx-20240812_pre.xml (EX-101.PRE) — 22KB
• tm2421304d1_8k_htm.xml (XML) — 4KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition On August 12, 2024, Leap Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2024. The full text of the press release issued by the Company in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation by reference language in such filing, unless expressly incorporated by specific reference to such filing. The information in this Current Report on Form 8-K, including the information set forth under this Item 2.02 and the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release of Leap Therapeutics, Inc. dated August 12, 2024. 104 Cover Page Interactive Data File. (Embedded within the Inline XBRL document.)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEAP THERAPEUTICS, INC. Dated: August 12, 2024 By: /s/ Douglas E. Onsi Name: Douglas E. Onsi Title: Chief Executive Officer and President

View Full Filing

View this 8-K filing on SEC EDGAR